Novartis AG Acquires Significant Stake in Tourmaline Bio, Inc.

Novartis AG has acquired a significant stake in Tourmaline Bio, Inc., as reported in the SEC filing. The filing indicates that Novartis AG, through its indirect wholly-owned subsidiary Torino Merger Sub Inc., now owns 24,030,382 shares of Tourmaline Bio's common stock. This acquisition represents a substantial investment in Tourmaline Bio, Inc., a company focused on developing innovative therapies. The filing was signed by attorneys Jonathan Emery and Ram Narayan on behalf of Novartis AG. The period of report is October 28, 2025. This transaction highlights Novartis AG's strategic interest in the biotechnology sector and its commitment to expanding its portfolio through significant investments.